Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Juarez

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Research Square|February 27, 2026
Bloodmeal metabarcoding reveals host feeding patterns for Aedes aegypti and Culex quinquefasciatus in Jutiapa, Guatemala and Texas, USAAbdisalam A Abdi, Sujata Balasubramanian, Jose Juarez, et al.
Cytotherapy|February 14, 2026
SMART sensors for cell growth monitoring in closed system G-Rex for scalable, cost-conscious cell and gene therapy manufacturingSubhanwit Roy, Samuel Rothstein, Aidan Shervheim, et al.
Frontiers in Oncology|November 9, 2023
Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implicationsVianey Rodriguez-Lara, Giovanny Soca-Chafre, Maria Rosa Avila-Costa, et al.
Plos One|January 28, 2014
Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM)Xiang Xu, Yuan Cai, Ying Wei, et al.
Pharmacoeconomics - Open|August 6, 2024
Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in MexicoDenisse Añorve Bailon, Javier Picó-Guzmán, Sergio Cifuentes, et al.
Journal of Medicinal Chemistry|July 20, 2016
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung CancersGérald Lelais, Robert Epple, Thomas H Marsilje, et al.
Nature|June 3, 2016
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsYong Jia, Cai-Hong Yun, Eunyoung Park, et al.
Journal of Cancer Research and Clinical Oncology|December 4, 2022
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomasJeronimo Rafael Rodriguez-Cid, Juan Jose Juarez-Vignon Whaley, Gisela Sánchez-Domínguez, et al.
Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.
Journal of Medicinal Chemistry|May 19, 2026
Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical ValidationDean P Phillips, Phil B Alper, Charles Y Cho, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Research Square|February 27, 2026
Bloodmeal metabarcoding reveals host feeding patterns for Aedes aegypti and Culex quinquefasciatus in Jutiapa, Guatemala and Texas, USAAbdisalam A Abdi, Sujata Balasubramanian, Jose Juarez, et al.
Cytotherapy|February 14, 2026
SMART sensors for cell growth monitoring in closed system G-Rex for scalable, cost-conscious cell and gene therapy manufacturingSubhanwit Roy, Samuel Rothstein, Aidan Shervheim, et al.
Frontiers in Oncology|November 9, 2023
Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implicationsVianey Rodriguez-Lara, Giovanny Soca-Chafre, Maria Rosa Avila-Costa, et al.
Plos One|January 28, 2014
Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM)Xiang Xu, Yuan Cai, Ying Wei, et al.
Pharmacoeconomics - Open|August 6, 2024
Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in MexicoDenisse Añorve Bailon, Javier Picó-Guzmán, Sergio Cifuentes, et al.
Journal of Medicinal Chemistry|July 20, 2016
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung CancersGérald Lelais, Robert Epple, Thomas H Marsilje, et al.
Nature|June 3, 2016
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsYong Jia, Cai-Hong Yun, Eunyoung Park, et al.
Journal of Cancer Research and Clinical Oncology|December 4, 2022
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomasJeronimo Rafael Rodriguez-Cid, Juan Jose Juarez-Vignon Whaley, Gisela Sánchez-Domínguez, et al.
Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.
Journal of Medicinal Chemistry|May 19, 2026
Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical ValidationDean P Phillips, Phil B Alper, Charles Y Cho, et al.
Pageof 2